Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
31.23
+0.02 (0.06%)
May 16, 2025, 4:00 PM - Market closed
Crinetics Pharmaceuticals Employees
Crinetics Pharmaceuticals had 437 employees as of December 31, 2024. The number of employees increased by 147 or 50.69% compared to the previous year.
Employees
437
Change (1Y)
147
Growth (1Y)
50.69%
Revenue / Employee
$1,739
Profits / Employee
-$751,149
Market Cap
2.93B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CRNX News
- 3 days ago - Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 - GlobeNewsWire
- 6 days ago - Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - GlobeNewsWire
- 5 weeks ago - Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha
- 7 weeks ago - Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly - GlobeNewsWire